Previous studies have correlated serum FABP5 with both the PASI score and the basic inflammatory index in psoriasis patients, indicating its potential as a marker for psoriasis severity and clinical outcomes post-treatment with NB-UVB (70, 71). This evidence concerns the gene FABP5 and psoriasis.